Researchers at the University of Texas have identified a significant link between low testosterone levels and an increased risk of developing aggressive forms of prostate cancer.
According to a study recently published in the Journal of Urology, men diagnosed with prostate cancer who maintain testosterone levels below 300 ng/dl have a 60% higher probability of their cancer progressing to grade three or higher. Tumors in this category are classified as aggressive, characterized by their ability to spread rapidly to other organs.
The Impact of Hormonal Levels on Cancer Progression
The research team reached these conclusions after analyzing data from a cohort study involving more than 900 men. The findings suggest that testosterone levels may be a more critical indicator of tumor aggression than several other traditional risk factors. Specifically, the study found that low testosterone had a greater influence on the risk of aggressive cancer than the patient’s age, body mass index (BMI), prostate-specific antigen (PSA) levels, or the size and density of the tumor itself.
These insights provide a deeper understanding of how hormonal health can influence the behavior of oncological growths, potentially allowing for better risk stratification in patients.
Understanding Prostate Cancer Risks
Prostate cancer remains the most common cancer among men in Germany, with approximately 80,000 people diagnosed annually as of 2023. While the majority of these tumors grow slowly and often remain asymptomatic in their early stages, the disease is not uniform.
Approximately 10% of patients suffer from a high-risk carcinoma. Unlike slow-growing tumors, these aggressive forms can deteriorate health quickly by invading other systems in the body. By identifying hormonal markers like low testosterone, medical professionals may be better equipped to distinguish between slow-growing cases and those requiring more urgent, aggressive intervention.
For more information on this discovery, you can view the original report: Prostata-Krebs: Zusammenhang zwischen aggressiven Tumoren und Testosteron entdeckt.
